Developing vaccines and treatments for dangerous viruses spread by mosquitoes
Official title: Core D: Animal Immunogenicity and Challenge
Funded at Washington University · NIH-10863000 · Data updated 2026-11-12
This study is working on developing better vaccines and treatments for serious illnesses like Dengue and Chikungunya, using animal models to find the best options that can also be quickly adjusted for new viruses in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 12, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $7,878,231 |
| NIH project number | 1U19AI181960-01 |
| Project ID | NIH-10863000 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk of infection from flaviviruses and alphaviruses, particularly those living in or traveling to endemic areas.
✕Less likely to help
Patients who are not at risk of exposure to these mosquito-borne viruses may not receive any benefit from this research.
What this research studies
This research focuses on creating effective vaccines and antibody treatments for severe diseases caused by flaviviruses and alphaviruses, such as Dengue and Chikungunya. Using animal models, the team will evaluate and refine vaccine candidates and monoclonal antibodies to ensure they are effective against these viruses. The goal is to establish flexible platforms that can quickly adapt to new viral threats as they emerge, addressing a critical need in global health.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines and treatments for diseases caused by mosquito-borne viruses, potentially saving millions of lives.
How similar studies have gone: Previous research has shown promise in developing vaccines for similar viral infections, indicating that this approach has the potential for success.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Streblow, Daniel N — Washington University
- Study coordinator: Streblow, Daniel N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.